WHAT IS CLAIMED IS:

1. A cold-adapted temperature sensitive virus strain EV71:eTLLβP20, EV71:TLLeC5 or TLLeCA16.

2. The cold-adapted temperature sensitive virus strain of claim 1, wherein the strain is EV71:eTLLβP20.

3. The cold-adapted temperature sensitive virus strain of claim 1, wherein the strain is EV71:TLLeC5.

4. The cold-adapted temperature sensitive virus strain of claim 1, wherein the strain is TLLeCA16.

5. A composition comprising one or more of the cold-adapted temperature sensitive virus strain of any one of claims 1 to 4.

6. The composition of claim 5 further comprising a cold-adapted temperature sensitive Enterovirus 71 strain EV71:TLLβP20

7. The composition of claim 5 or 6 which further comprises a pharmaceutically acceptable carrier.

8. The composition of claim 5, 6 or 7 which further comprises an adjuvant.

9. The composition of any one of claims 5 to 8 which is a vaccine.

10. The composition of claim 9, wherein the vaccine is an oral live attenuated vaccine.

11. The composition of claim 9, wherein the vaccine is an inactivated vaccine.

12. A cold-adapted temperature sensitive virus strain of any one of claims 1 to 4 or a composition of any one of claims 5 to 11 for use in eliciting a protective immune response in a subject.

13. A cold-adapted temperature sensitive virus strain of any one of claims 1 to 4 or a composition of any one of claims 5 to 11 for use in preventing a subject from becoming afflicted with an Enterovirus 71-associated disease and/or a Coxsackievirus A16-associated disease.

14. A cold-adapted temperature sensitive virus strain of any one of claims 1 to 4 or a composition of any one of claims 5 to 11 for use in delaying the onset of or slowing the rate of an Enterovirus 71-associated disease and/or a Coxsackievirus A16-associated disease in an Enterovirus 71-infected subject and/or a Coxsackievirus A16-infected subject.

15. The cold-adapted temperature sensitive virus strain of any one of claims 12 to 14 or the composition of any one of claims 12-14, wherein the subject has been exposed to wild-type Enterovirus 71 and/or a Coxsackievirus A16.

16. The cold-adapted temperature sensitive virus strain of any one of claims 12 to 15 or the composition of any one of claims 12-15, wherein the subject is a human subject.

17. Use of cold-adapted temperature sensitive virus strain of any one of claims 1 to 4 or an inactivated form thereof, or a composition of any one of claims 5 to 11 for the manufacture of a medicament for eliciting a protective immune response in a subject.

18. Use of cold-adapted temperature sensitive virus strain of any one of claims 1 to 4 or an inactivated form thereof, or a composition of any one of claim 5 to 11 for the manufacture of a medicament for preventing a subject from becoming afflicted with an Enterovirus 71-associated disease and/or a Coxsackievirus A16-associated disease.

19. Use of cold-adapted temperature sensitive Enterovirus 71 strain of any one of claims 1 to 4 or an inactivated form thereof, or a composition of any one of claim 5 to 11 for the

manufacture of a medicament for delaying the onset of or slowing the rate of an Enterovirus 71-associated disease and/or a Coxsackievirus A16-associated disease in an Enterovirus 71-infected subject and/or a Coxsackievirus A16-infected subject.

20. The use of any one of claims 17 to 19, wherein the subject has been exposed to wild-type Enterovirus 71 and/or a Coxsackievirus A16.

21. The use of any one of claims 17 to 20, wherein the subject is a human subject.

22. A kit for immunization of a subject with of a cold-adapted temperature sensitive virus strain comprising the cold-adapted temperature sensitive virus strain of any one of claims 1 to 4 or an inactivated form thereof, or a composition of any one of claims 5 to 11, a pharmaceutically acceptable carrier, and an instructional material for the use thereof.

23. The kit of claim 22 which further comprises an applicator.

24. A method of making a vaccine comprising using the cold-adapted temperature sensitive virus strain of any one of claims 1 to 4 or an inactivated form thereof.

25. A method of making a vaccine comprising using one or more nucleic acids comprising the nucleotide sequence set forth in SEQ ID NO: 84, SEQ ID NO: 86 or SEQ ID NO: 88.

26. The method of claim 25 further comprising using a nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO: 83.

27. Use of the cold-adapted temperature sensitive virus strain of any one of claims 1 to 4 for vaccine development or an inactivated form thereof.

28. Use of one or more nucleic acids comprising the nucleotide sequence set forth in SEQ ID NO: 84, SEQ ID NO: 86 or SEQ ID NO: 88 for vaccine development.

29. The use of claim 28 further comprising a nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO: 83.

30. A cold-adapted temperature sensitive virus strain of any one of claims 1 to 4 or an inactivated form thereof for use in vaccine development.

31. A nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO: 84, SEQ ID NO: 86 or SEQ ID NO: 88 for use in vaccine development.

32. Use of the cold-adapted temperature sensitive virus strain of any one of claims 1 to 4 or an inactivated form thereof.

33. Use of a nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO: 84, SEQ ID NO: 86 or SEQ ID NO: 88.

34. An isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO: 84, SEQ ID NO: 86 or SEQ ID NO: 88.

35. A virus vector comprising the nucleotide sequence set forth in SEQ ID NO: 84, SEQ ID NO: 86 or SEQ ID NO: 88